Paulus  Stoffels net worth and biography

Paulus Stoffels Biography and Net Worth

Paul studied Medicine at the University of Diepenbeek and the University of Antwerp in Belgium and Infectious Diseases and Tropical Medicine at the Institute of Tropical Medicine in Antwerp, Belgium.
Paul began his career as a physician in Africa, focusing on HIV and tropical diseases clinical research, and worked at Janssen Pharmaceutica under the tutelage of Dr. Paul Janssen in the early 1990s. He re-joined Johnson & Johnson in 2002 with the acquisition of Virco and Tibotec, where he led the development of several breakthrough products for the treatment of HIV that helped to transform this devastating, deadly disease into a chronic and treatable condition.

What is Paulus Stoffels' net worth?

The estimated net worth of Paulus Stoffels is at least $51.71 million as of February 15th, 2018. Dr. Stoffels owns 357,906 shares of Johnson & Johnson stock worth more than $51,706,680 as of December 21st. This net worth evaluation does not reflect any other assets that Dr. Stoffels may own. Learn More about Paulus Stoffels' net worth.

How do I contact Paulus Stoffels?

The corporate mailing address for Dr. Stoffels and other Johnson & Johnson executives is ONE JOHNSON & JOHNSON PLZ, NEW BRUNSWICK NJ, 08933. Johnson & Johnson can also be reached via phone at (732) 524-0400 and via email at [email protected]. Learn More on Paulus Stoffels' contact information.

Has Paulus Stoffels been buying or selling shares of Johnson & Johnson?

Paulus Stoffels has not been actively trading shares of Johnson & Johnson during the last ninety days. Most recently, Paulus Stoffels sold 155,342 shares of the business's stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $129.86, for a transaction totalling $20,172,712.12. Following the completion of the sale, the vice president now directly owns 357,906 shares of the company's stock, valued at $46,477,673.16. Learn More on Paulus Stoffels' trading history.

Who are Johnson & Johnson's active insiders?

Johnson & Johnson's insider roster includes Dominic Caruso (VP), Robert Decker (CAO), Joaquin Duato (CEO & Chairman), Peter Fasolo (VP), Alex Gorsky (CEO), William Hait (Insider), Ronald Kapusta (CAO), Ashley McEvoy (EVP), Thibaut Mongon (VP), William Perez (Director), Michael Sneed (COO), Paulus Stoffels (VP), James Swanson (EVP), Jennifer Taubert (EVP), Mark Weinberger (Director), Kathryn Wengel (EVP), Joseph Wolk (CFO), and Joseph Wolk (Exec. VP & CFO ). Learn More on Johnson & Johnson's active insiders.

Are insiders buying or selling shares of Johnson & Johnson?

During the last year, Johnson & Johnson insiders bought shares 1 times. They purchased a total of 1,000 shares worth more than $147,220.00. During the last year, insiders at the sold shares 3 times. They sold a total of 68,757 shares worth more than $10,308,224.54. The most recent insider tranaction occured on December, 12th when Director Mark A Weinberger bought 1,000 shares worth more than $147,220.00. Insiders at Johnson & Johnson own 0.2% of the company. Learn More about insider trades at Johnson & Johnson.

Information on this page was last updated on 12/12/2024.

Paulus Stoffels Insider Trading History at Johnson & Johnson

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/15/2018Sell155,342$129.86$20,172,712.12357,906View SEC Filing Icon  
7/24/2017Sell102,692$133.14$13,672,412.88230,342View SEC Filing Icon  
2/15/2017Sell22,000$117.29$2,580,380.00127,650View SEC Filing Icon  
2/17/2016Sell125,000$102.43$12,803,750.00122,543View SEC Filing Icon  
4/28/2015Sell187,250$100.73$18,861,692.50View SEC Filing Icon  
7/25/2013Sell45,440$92.40$4,198,656.00View SEC Filing Icon  
See Full Table

Paulus Stoffels Buying and Selling Activity at Johnson & Johnson

This chart shows Paulus Stoffels's buying and selling at Johnson & Johnson by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Johnson & Johnson Company Overview

Johnson & Johnson logo
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Read More

Today's Range

Now: $144.47
Low: $142.75
High: $145.47

50 Day Range

MA: $155.16
Low: $143.58
High: $165.86

2 Week Range

Now: $144.47
Low: $142.75
High: $168.85

Volume

17,607,496 shs

Average Volume

7,204,668 shs

Market Capitalization

$347.83 billion

P/E Ratio

20.91

Dividend Yield

3.39%

Beta

0.51